The structure based drug design for controlling the innate immune response and interleukin-18 signaling.

MyD 88是Toll样受体和IL-1/18信号通路中的重要衔接分子。在本研究中，我们试图创建分子，调节这些免疫信号反应，基于我们确定的蛋白质结构和蛋白质相互作用的研究结果MyD 88。在此期间，我们可以开发出几种方法，直接研究蛋白质-蛋白质相互作用的TIR结构域包含的分子。在此基础上，我们构建了一个新的分子，即含有显性负性形成的蛋白转导结构域MyD 88（PTD-MyD 88-DN）。我们将继续以MyD 88为靶点的药物开发。

MyD88 is the important adaptor molecule in the Toll like receptors and IL-1/18 signaling pathways. In this study, we tried to create the molecule, which regulate these immune signaling response, based on the results of our decided protein structure of MyD88 and protein interaction studies. In the duration of this research aid, we could develop the several methods of direct protein-protein interaction studies with the TIR domain containing molecules. Furthermore, we created the new molecule, protein transduction domain containing dominant negative formed MyD88 (PTD-MyD88-DN). We will continue the drug development that assumed MyD88 a target.